top of page
media-generation-bach-hero-tme-0-60e5bb20-9b84-47e9-95f3-c8ea1dc279e9.webp
Smarter cancer drugs, activated at the tumor.
 
A drug discovery company built on fibroblast activation protein (FAP) science — our platforms turn potent therapies on at the tumor site and keep them quiet everywhere else. Boston, Massachusetts.
media-generation-bach-about-enzyme-0-27907d8c-ce8b-4f07-9652-ff1ae50105a0.webp

About Bach BioSciences

Bach BioSciences, LLC is a mission-driven drug discovery and development company founded in 2018 by William W. Bachovchin, PhD, Professor of Molecular and Chemical Biology at Tufts University School of Medicine. The company is built around Dr. Bachovchin's laboratory research on serine proteases — in particular fibroblast activation protein (FAP), an enzyme expressed on cancer-associated fibroblasts in the tumor microenvironment of more than 90% of epithelial cancers, but largely absent from normal tissues. Bach BioSciences holds the patent portfolio for FAP-activated prodrug and FAP-targeted radiotheranostic technologies, and advances them through licensing and collaboration with global partners.
Home: About Me
Home: Research

Technology & Programs

Three platform technologies exploit FAP in complementary ways — as a tumor-specific activating enzyme, and as a tumor-localizing target.
media-generation-bach-tmac-activation-0-99ed343f-cf82-4ab7-91b6-6d6e9ddde2c6.webp

TMACs — Tumor Microenvironment-Activated Compounds

Prodrugs that circulate in an inactive form and are cleaved by FAP at the tumor, releasing the active drug where it is needed. Example: AVA6000 (faridoxorubicin), a FAP-activated doxorubicin prodrug licensed to Avacta as the foundation of its pre|CISION platform — now in Phase 1b clinical trials, with encouraging efficacy signals in salivary gland cancer and none of the severe cardiac toxicity that limits conventional doxorubicin.
media-generation-bach-tmeld-pet-0-3f08178e-3930-443b-b218-a5a8ed11e182.webp

TMELDs — Tumor Microenvironment-Localized Drugs

Agents that bind FAP and concentrate at the tumor rather than being activated by it, including radiotheranostics that deliver imaging and therapeutic isotopes. Example: PNT6555, a boronic-acid-based FAP-targeted radiotheranostic licensed to POINT Biopharma — now part of Eli Lilly — and in Phase 1 clinical trials (the FRONTIER trial).
media-generation-bach-canseek-dual-0-dd3ebda4-17c4-4b7d-ab59-cf23bb5364bc.webp

Can-SEEK

FAP-activated, tumor-antigen-targeted radiotheranostics — combining FAP selectivity with a second targeting layer (such as PSMA or folate receptor) for an additional margin of tumor specificity. Licensed to POINT Biopharma, with foundational technology also licensed from Avacta.

Partnerships & Licensed Programs

Avacta (UK) — Exclusive licensee of Bach's FAP-cleavable prodrug platform (2018), developed as the pre|CISION platform. Licensed program: AVA6000 (faridoxorubicin) — Phase 1b.
 
POINT Biopharma — now part of Eli Lilly — Exclusive licensee of Bach's FAP-targeted radiopharmaceutical technology (April 2020). POINT was acquired by Eli Lilly and Company in December 2023. Licensed programs: PNT6555 (Phase 1), PNT6522, PNT3090, and the Can-SEEK program.
 
Tract Bio — Ongoing research collaboration applying Bach's FAP-activated prodrug technology to new drug candidates.
 
Licensed programs: AVA6000 — Avacta — Phase 1b | PNT6555 — POINT / Eli Lilly — Phase 1 | PNT6522 — POINT / Eli Lilly | PNT3090 — POINT / Eli Lilly

Leadership

William W. Bachovchin, PhD — Founder, President & Chief Scientist. Professor of Molecular and Chemical Biology at Tufts University School of Medicine. Inventor of the FAP-targeting technologies licensed from Bach BioSciences; his laboratory's work spans serine protease mechanism, NMR structural studies, and the rational design of protease-activated therapeutics.
Home: Publications

Publications

30 Nov 2023 Journal of Nuclear Medicine
DOI: https://doi.org/10.2967/jnumed.123.266345

Joe A.B. McCann and William W. Bachovchin Sarah E. Poplawski, Robin M. Hallett, Mark H. Dornan, Kyle E. Novakowski, Shuang Pan, Anthony P. Belanger, Quang-De Nguyen, Wengen Wu, Albert E. Felten, Yuxin Liu, Shin Hye Ahn, Valerie S. Hergott, Barry Jones, Jack H. Lai

 2021 Nov 1;13(21):5495.

 doi: 10.3390/cancers13215495.

Henderson JM, Xiang MSW, Huang JC, Wetzel S, Jiang L, Lai JH, Wu W, Kench JG, Bachovchin WW, Roediger B, McCaughan GW, Zhang HE, Gorrell MD

2021 Jan:177:105766.

 doi: 10.1016/j.pep.2020.105766. Epub 2020 Sep 25.

Shin J, Phelan PJ, Gjoerup O, Bachovchin W, Bullock PA 

Contact

Thanks for submitting!

For partnering and licensing inquiries, please use the form below. Bach BioSciences, LLC, 75 Kneeland Street, 14th Floor, Boston, MA 02111.
Home: Contact
  • Facebook
  • Twitter
  • LinkedIn
© 2026 Bach BioSciences, LLC. All rights reserved.
bottom of page